Lenvatinib for Advanced Bone and Soft Tissue Sarcoma
Status:
Not yet recruiting
Trial end date:
2025-06-30
Target enrollment:
Participant gender:
Summary
A total of 60 patients with metastatic/surgically unresectable bone and soft tissue sarcomas
who had previously received multi-target TKI therapy and failed were enrolled to evaluate the
efficacy and safety.